Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,773.50
Bid: 1,772.00
Ask: 1,772.50
Change: 12.50 (0.71%)
Spread: 0.50 (0.028%)
Open: 1,770.00
High: 1,776.00
Low: 1,766.00
Prev. Close: 1,761.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

MARKET COMMENT: UK Stocks To Open Higher Ahead Of BoE Minutes

Wed, 22nd Oct 2014 06:35

LONDON (Alliance News) - UK stocks are set to open higher Wednesday, following gains made in the US and Asia and ahead of the release of the minutes from the October meeting of the Monetary Policy Committee of the Bank of England.

Futures indicate the FTSE 100 will open 20 points higher at 6,392.

The UK's leading index, along with other major European indices, made significant gains on Tuesday amid reports that the European Central Bank is looking to take further steps to boost the slowing eurozone economy. Reuters reported that the ECB is considering buying bonds in the secondary market as part of its effort to boost lending in the single currency block. The central bank could take a decision as soon as December, Reuters said.

"The fact that story pushed equities up should be further evidence that it is central banks, not fundamentals, driving market momentum at the moment," says Rabobank analyst Michael Every.

Equity markets have seen a significant increase in volatility recently as investors show their nervousness over whether the global economy is strong enough to stand on its own two feet, without the extra support of the US quantitative easing programme that ends this month.

Hope of further stimulus was enough to help US investors look past mixed earnings and push Wall Street higher. The DJIA gained 1.3% higher, the S&P 500 2.0%, and the Nasdaq Composite 2.4%.

US Technology bellwether Yahoo Inc beat estimates on Tuesday by reporting third quarter earnings per share of USD0.52, much better than the USD0.30 that had been forecast by analysts. The profit includes a 6.3-billion-dollar gain from Yahoo's sale of a stake in the Alibaba Group, as part of the Chinese company's initial public offering in September.

Not all US earnings were so positive however, with McDonald's Corp, for example, reporting earnings per share of USD1.09 in the third quarter, down from USD1.52 last year and missing expectations for USD1.37.

It has been a positive Asian session so far Wednesday, with the Nikkei closing up about 2.5%, while the Hang Seng continues up 1.4%, and the Shanghai Composite is fractionally higher.

The domestic economic focus in the UK Wednesday is the release of the minutes from the latest MPC meeting at the Bank of England. The committee elected to keep the UK base rate on hold at a record low of 0.5% at the meeting earlier this month, but given that two of its members voted for a rate rise in September, investors will be keen to see how the vote was split this month. Given the recent market volatility, calls for rate rises have been somewhat subdued and the consensus expectation is for an unchanged 7-2 vote to keep rates on hold.

One of BoE's most notable hawks, Martin Weale, will be speaking after the market close at 2000 BST in Cambridge. Weale and Ian McCafferty were the two Monetary Policy Committee members to vote for a rate rise last month.

From the UK corporate calendar Wednesday, British American Tobacco has joined the list of names highlighting the impact of the strength of the pound on its earnings. The cigarette maker said its nine-month revenue was up 2.4% at constant exchange rates but down 9.6% at actual rates.

Updates are also out Wednesday from Playtech, International Personal Finance, and Spirit Pub Co. GlaxoSmithKline is reporting third-quarter earnings at 1200 BST.

In the afternoon, the attention will shift to the US where third quarter earnings season continues with a multitude of names including AT&T Inc and Boeing Company reporting.

US consumer price inflation at 1330 BST will be of key interest given the heightened concerns over the strength of the economy as stimulus is withdrawn. The expectation is for a slight fall in CPI to 1.6% year-on-year in September, from 1.7% in August. The US, like the UK, targets 2.0% inflation, and anything greater than the expected 0.1% fall will likely cause some concern, analysts say.

By Jon Darby; jondarby@alliancenews.com; @jondarby100

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more
10 Jan 2024 07:22

GSK's Nucala gets fresh approval in China

(Sharecast News) - GSK announced on Wednesday that the China National Medical Products Administration (NMPA) has granted approval for 'Nucala', or mepolizumab, as an add-on maintenance treatment for severe eosinophilic asthma in adults and adolescents aged 12 years and older.

Read more
9 Jan 2024 16:22

London close: Stocks finish red after choppy session

(Sharecast News) - London stocks had turned back into the red by the close on Tuesday, with recruitment firms and asset managers pacing the declines after some disappointing corporate updates.

Read more
9 Jan 2024 08:03

TOP NEWS: GSK to buy Aiolos Bio for up to USD1.4 billion

(Alliance News) - GSK PLC on Tuesday said it will acquire asthma drug developer Aiolos Bio Inc for USD1 billion upfront, as well as up to USD400 million in certain success-based milestone payments.

Read more
9 Jan 2024 07:16

GSK buys respiratory drug maker Aiolos for $1bn

(Sharecast News) - GSK said it was buying Aiolos, a clinical-stage biopharmaceutical company focused on treatment of respiratory and inflammatory conditions, for up to $1.4bn (£1.1bn).

Read more
8 Jan 2024 23:39

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more
8 Jan 2024 23:00

Pfizer to remain aggressive on obesity market after setback

NEW YORK, Jan 8 (Reuters) - Pfizer will remain aggressive in trying to break into the lucrative obesity market, even after dropping a high profile weight-loss drug candidate late last year due to strong side effects, Chief Executive Albert Bourla said on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.